Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients with Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy after EGFR Inhibition

MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi). However, MET amplification has been inconsistently defined and frequently included both polysomy and true amplification.